Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma - PubMed (original) (raw)
D Stephen Charnock-Jones, Diana Licence, Atsushi Yanaihara, Julie M Hastings, Cathrine M Holland, Makoto Emoto, Akiko Sakamoto, Tomomi Sakamoto, Hidetoshi Maruyama, Shigemi Sato, Hideki Mizunuma, Stephen K Smith
Affiliations
- PMID: 12684405
Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma
Yoshihito Yokoyama et al. Clin Cancer Res. 2003 Apr.
Abstract
Purpose: To evaluate the prognostic value of vascular endothelial growth factor (VEGF)-D and VEGF receptor (VEGFR)-3 in endometrial carcinoma.
Experimental design: We assessed the levels of immunoreactivity for VEGF-D and VEGFR-3 in 71 endometrial carcinomas, 14 complex atypical endometrial hyperplasias, and 16 normal endometria by immunohistochemistry.
Results: VEGF-D was stained in both tumor cells and adjacent stromal cells. VEGFR-3 was stained in both tumor cells and adjacent endothelial cells. Immunoreactivity for VEGF-D in tumor cells and adjacent stromal cells became significantly stronger as lesions progressed from normal endometrium to advanced carcinoma. Similarly, immunoreactivity for VEGFR-3 in tumor cells and adjacent endothelial cells was significantly greater as lesions progressed from normal endometrium to advanced carcinoma. A strong correlation was found between high levels of VEGF-D immunoreactivity in carcinoma cells and VEGFR-3 in both carcinoma cells and adjacent endothelial cells. Similarly, high levels of VEGF-D immunoreactivity in stromal cells were significantly correlated with those of VEGFR-3 in both carcinoma cells and endothelial cells. High levels of VEGF-D in carcinoma cells and stromal cells, as well as those of VEGFR-3 in carcinoma cells and endothelial cells, were significantly related to myometrial invasion and lymph node metastasis. A strong correlation was found between poor survival and high levels of VEGF-D in both carcinoma cells and stromal cells and between poor survival and high levels of VEGFR-3 in carcinoma cells. Moreover, the high levels of VEGF-D in stromal cells and VEGFR-3 in carcinoma cells were independent prognostic factors in endometrial carcinoma.
Conclusions: The presence of VEGF-D and VEGFR-3 in endometrial carcinoma may predict myometrial invasion and lymph node metastasis and may prospectively identify patients who are at increased risk for poor outcome. In addition, VEGF-D and VEGFR-3 may be promising targets for new therapeutic strategies in endometrial carcinoma.
Similar articles
- Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma.
Jüttner S, Wissmann C, Jöns T, Vieth M, Hertel J, Gretschel S, Schlag PM, Kemmner W, Höcker M. Jüttner S, et al. J Clin Oncol. 2006 Jan 10;24(2):228-40. doi: 10.1200/JCO.2004.00.3467. Epub 2005 Dec 12. J Clin Oncol. 2006. PMID: 16344322 - Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
Kato H, Yoshikawa M, Miyazaki T, Nakajima M, Fukai Y, Masuda N, Fukuchi M, Manda R, Tsukada K, Kuwano H. Kato H, et al. Anticancer Res. 2002 Nov-Dec;22(6C):3977-84. Anticancer Res. 2002. PMID: 12553021 - Clinicopathological and prognostic significance of vascular endothelial growth factors (VEGF)-C and -D and VEGF receptor 3 in invasive breast carcinoma.
Mylona E, Alexandrou P, Mpakali A, Giannopoulou I, Liapis G, Markaki S, Keramopoulos A, Nakopoulou L. Mylona E, et al. Eur J Surg Oncol. 2007 Apr;33(3):294-300. doi: 10.1016/j.ejso.2006.10.015. Epub 2006 Nov 28. Eur J Surg Oncol. 2007. PMID: 17129704 - Angiogenesis and endometrial cancer.
Sivridis E. Sivridis E. Anticancer Res. 2001 Nov-Dec;21(6B):4383-8. Anticancer Res. 2001. PMID: 11908694 Review. - Malignant endometrial pathology.
Nieberg RK, Hirschowitz SL. Nieberg RK, et al. Curr Opin Obstet Gynecol. 1992 Aug;4(4):594-600. Curr Opin Obstet Gynecol. 1992. PMID: 1504278 Review.
Cited by
- Stromal-derived MAOB promotes prostate cancer growth and progression.
Pu T, Wang J, Wei J, Zeng A, Zhang J, Chen J, Yin L, Li J, Lin TP, Melamed J, Corey E, Gao AC, Wu BJ. Pu T, et al. Sci Adv. 2024 Feb 9;10(6):eadi4935. doi: 10.1126/sciadv.adi4935. Epub 2024 Feb 9. Sci Adv. 2024. PMID: 38335292 Free PMC article. - Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets.
Thiel KW, Newtson AM, Devor EJ, Zhang Y, Malmrose PK, Bi J, Losh HA, Davies S, Smith LE, Padilla J, Leiva SM, Grueter CE, Breheny P, Hagan CR, Pufall MA, Gertz J, Guo Y, Leslie KK. Thiel KW, et al. J Steroid Biochem Mol Biol. 2023 Nov;234:106399. doi: 10.1016/j.jsbmb.2023.106399. Epub 2023 Sep 15. J Steroid Biochem Mol Biol. 2023. PMID: 37716459 Free PMC article. - Vascular Endothelial Growth Factor-D (VEGF-D): An Angiogenesis Bypass in Malignant Tumors.
Bokhari SMZ, Hamar P. Bokhari SMZ, et al. Int J Mol Sci. 2023 Aug 28;24(17):13317. doi: 10.3390/ijms241713317. Int J Mol Sci. 2023. PMID: 37686121 Free PMC article. Review. - Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis.
Vimalraj S, Hariprabu KNG, Rahaman M, Govindasami P, Perumal K, Sekaran S, Ganapathy D. Vimalraj S, et al. 3 Biotech. 2023 Oct;13(10):326. doi: 10.1007/s13205-023-03719-4. Epub 2023 Sep 1. 3 Biotech. 2023. PMID: 37663750 Free PMC article. Review. - VEGF Immunoexpression in Endometrioid Endometrial Carcinomas.
Drocaş I, Crăiţoiu Ş, Stepan AE, Simionescu CE, Marinescu D. Drocaş I, et al. Curr Health Sci J. 2022 Apr-Jun;48(2):155-161. doi: 10.12865/CHSJ.48.02.03. Epub 2022 Jun 30. Curr Health Sci J. 2022. PMID: 36320870 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous